Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Exelixis drug improves...

    Exelixis drug improves overall survival in liver cancer patients

    Written by Ruby Khatun Khatun Published On 2017-10-21T09:12:06+05:30  |  Updated On 18 Aug 2021 3:33 PM IST

    Exelixis Inc's drug to treat a type of liver cancer improved overall survival in patients in a late-stage study that prompted an independent expert group to recommend no further trial, sending the company's shares soaring 31 percent.


    The recommendation by the external data monitoring committee for terminating a trial typically paves the way for companies to get early regulatory approvals for their treatments in the United States.



    In the latest trial, the drug, cabozantinib, showed statistically significant improvement in overall survival in advanced hepatocellular carcinoma (HCC) patients who had been previously treated with Bayer and Amgen's sorafenib, as compared with a placebo, the company said.

    "With this clinical hurdle removed, we view the company as one of the prime takeout targets," William Blair analyst Andy Hsieh wrote in a client note.


    Exelixis, which has a market value of about $7.30 billion, plans to file for an expanded label with the U.S. Food and Drug Administration in the first quarter of 2018.


    Hsieh said the drug's success in the late-stage trial should help the company penetrate the $1.1 billion global market for HCC.


    The drug was approved for treating kidney cancer in 2016 and is sold under the brand name Cabometyx.


    The market for HCC drugs is heating up following recent approvals of Bristol-Myers Squibb's blockbuster immunotherapy, Opdivo, and Bayer AG's Stivarga.


    Sorafenib, sold under the brand name Nexavar, was approved to treat liver cancer in 2007.


    "As is typical protocol, we will speak with FDA about stopping the trial, so that patients can cross over," Exelixis spokeswoman Susan Hubbard told Reuters.


    About 40,710 people will be diagnosed with liver cancers in 2017 and about 28,920 will die of the diseases, according to the National Cancer Institute.


    Exelixis' shares were trading at $32.50 in morning trading on Monday. They have risen 86.2 percent since the beginning of the year.




    (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Anil D'Silva)



    AmgenBayerBristol-MyersCabometyxcabozantinibdrugExelixishepatocellular carcinomakidney cancerliver cancerNational Cancer InstituteNexavarOpdivopharma newssorafenibStivargasurvivalU.S. Food and Drug Administration
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok